With the aim of further studying the role of RIPK1 in the pathogenesis of DG, pre-clinical in vitro assays were performed using the human glioblastoma cell line U251 and the highly selective commercial RIPK1 inhibitor, GSK2982772. The gene discussed is RIPK1; the disease is glioblastoma.